Effective bladder preservation strategy with low-dose radiation therapy and concurrent intrarrterial chemotherapy for muscle-invasive bladder cancer

Radiation Medicine - Medical Imaging and Radiation Oncology

Volumn 26, Issue 3, 2008, Pages 156-163

  Ikushima, Hitoshi ^a   Iwamoto, Seiji ^a   Osaki, Kyohsuke ^a   Furutani, Shunsuke ^a   Yamashita, Kyoh ^a   Kawanaka, Takashi ^a   Kubo, Akiko ^a   Takegawa, Yoshihiro ^a   Kudoh, Takaharu ^a   Kanayama, Hiroomi ^a   Nishitani, Hiromu ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Bladder cancer; Bladder preservation; Chemoradiotherapy; Intraarterial chemotherapy; Multimodality therapy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PIRARUBICIN; VINBLASTINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER MUSCLE; BLOOD TOXICITY; BONE METASTASIS; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYSTECTOMY; DIARRHEA; DISEASE COURSE; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MALE; MULTIPLE CYCLE TREATMENT; ORGAN PRESERVATION; RADIATION DOSE; SINUS TACHYCARDIA; SKIN TOXICITY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT DISEASE; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYSTECTOMY; FEMALE; HUMANS; INFUSIONS, INTRA-ARTERIAL; MALE; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 43249123382     PISSN: 02882043     EISSN: 18625274     Source Type: Journal    
DOI: 10.1007/s11604-007-0211-x     Document Type: Article

References (32)

1. Tester W, Porter A, Asbell S, Coughlin C, Heaney J, Krall J, et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 1993;25:783-790.
2. Tester W, Caplan R, Heaney J, Venner P, Whittington R, Byhardt R, et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of radiation therapy oncology group phase II trial 8802. J Clin Oncol 1996;14:119-126.
3. Shipley WU, Winter KA, Kaufman DS, Lee WR, Heney NM, Tester WR, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998;16:3576-3583.
4. Kaufman DS, Winter KA, Shipley WU, Heney NM, Chetner MP, Souhami L, et al. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 2000;5:471-476.
5. Hagan MP, Winter KA, Kaufman DS, Wajsman Z, Zietman AL, Heney NM, et al. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 2003:57:665-672.
6. Sauer R, Birkenhake S, Kuhn R, Wittekind C, Schrott KM, Martus P, et al. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int J Radiat Oncol Biol Phys 1998:40:121-127.
7. Michaelson MD, Shipley WU, Heney NM, Zietman AL, Kaufman DS. Selective bladder preservation for muscleinasive transitional cell carcinoma of the urinary bladder. Br J Cancer 2004;90:578-581.
8. Shipley WU, Kaufman DS, Zehr E, Heney NM, Lane SC, Thakral HK, et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002;60:62-67.
9. Rodel C, Grabenbauer GG, Kuhn R, Papadopoulos T, Dunst J, Meyer M, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002;20:3061-3071.
10. Rodel C, Grabenbauer GG, Kuhn R, Zorcher T, Papadopoulos T, Dunst J, et al. Organ preservation in patients with invasive bladder cancer: initial results of an intensified protocol of transurethral surgery and radiation therapy plus concurrent cisplatin and 5-fluorouracil. Int J Radiat Oncol Biol Phys 2002;52:1303-1309.
11. Fleming ID, Cooper JS, Henson DE, editors. AJCC cancer staging manual. 5th edition. Philadelphia: Lippincott-Raven; 1997. p. 241-243.
12. Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, et al. Common toxicity criteria, version 2.0: an improved reference for grading the acute effects of cancer treatment-impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000;47:13-47.
13. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-1346.
14. Dalbagni G, Genega E, Hashibe M, Zhang ZF, Russo P, Herr H, et al. Cystectomy for bladder cancer: a contemporary series. J Urol 2001;165:1111-1116.
15. Quek ML, Stein JP, Nichols PW, Cai J, Miranda G, Groshen S, et al. Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy. J Urol 2005;174:103-106.
16. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666-675.
17. Shearer RJ, Chilvers CF, Bloom HJ, Bliss JM, Horwich A, Babiker A, et al. Adjuvant chemotherapy in T3 carcinoma of the bladder: a prospective trial; preliminary report. Br J Urol 1988;62:558-564.
18. Gospodarowicz MK, Hawkins NV, Rawlings GA, Connolly JG, Jewett MA, Thomas GM, et al. Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis. J Urol 1989;142:1448-1453.
19. Pollack A, Zagars GK, Swanson DA. Muscle-invasive bladder cancer treated with external beam radiotherapy: prognostic factors. Int J Radiat Oncol Biol Phys 1994;30:267-277.
20. Jenkins BJ, Caulfield MJ, Fowler CG, Badenoch DF, Tiptaft RC, Paris AM, et al. Reappraisal of the role of radical radiotherapy and salvage cystectomy in the treatment of invasive (T2/T3) bladder cancer. Br J Urol 1988;62:343-346.
21. Sell A, Jakobsen A, Nerstrom B, Sorensen BL, Steven K, Barlebo H, et al. Treatment of advanced bladder cancer category T2 T3 and T4a: a randomized multicenter study of preoperative irradiation and cystectomy versus radical irradiation and early salvage cystectomy for residual tumor. DEVECA protocol 8201; Danish Vesical Cancer Group. Scand J Urol Nephrol Suppl 1991;138:193-201.
22. Mameghan H, Fisher R, Mameghan J, Brook S. Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys 1995;31:247-254.
23. Eapen L, Stewart D, Danjoux, Genest P, Futter N, Moors D, et al. Intraarterial cisplatin and concurrent radiation for locally advanced bladder cancer. J Clin Oncol 1989;7:230-235.
24. Mokarim A, Uetani M, Hayashi N, Sakamoto I, Minami K, Ogawa Y, et al. Combined intraarterial chemotherapy and radiotherapy in the treatment of bladder carcinoma. Cancer 1997;80:1776-1785.
25. Sumiyoshi Y, Hashine K, Karashima T, Kasahara K, Inoue Y. Preliminary results of bladder preservation by concurrent intraarterial chemotherapy and radiotherapy for muscle-invasive bladder cancer. Int J Urol 1998;5:225-229.
26. Miyanaga N, Akaza H, Okumura T, Sekido N, Kawai K, Shimizu T, et al. A bladder preservation regimen using intraarterial chemotherapy and radiotherapy for invasive bladder cancer: a prospective study. J Clin Oncol 1989;7:230-235.
27. Sumiyoshi Y. Chemoradiotherapy as a bladder-preservation approach for muscle-invasive bladder cancer: current status and perspectives. Int J Clin Oncol 2004;9:484-490.
28. Eapen L, Stewart D, Collins J, Peterson R. Effective bladder sparing therapy with intra-arterial cisplatin and radiotherapy for localized bladder cancer. J Urol 2004;172:1276-1280.
29. Ghersi D, Stewart LA, Parmer MKB, Coppin C, Martinezpineiro J, Raghavan D, et al. Dose neoadjuvant cisplatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer: a meta-analysis of individual patient data from randomized clinical trials. Br J Urol 1995;75:206-213.
30. International Collaboration of Trialists on Behalf of the Medical Research Council Advanced Bladder Cancer Working Party: neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer; a randomized controlled trial. Lancet 1999;354:533-540.
31. Skinner DG, Daniel JR, Russel CA, Lieskovsky G, Boyd SD, Nichols P, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991;145:459-467.
32. Anonymous. Advanced bladder cancer meta-analysis collaboration: neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003;361:1922-1923.